tradingkey.logo

Immunoprecise Antibodies Ltd

IPA
View Detailed Chart

2.070USD

0.000
Close 09/19, 16:00ETQuotes delayed by 15 min
95.54MMarket Cap
LossP/E TTM

Immunoprecise Antibodies Ltd

2.070

0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

0.00%

1 Month

-19.46%

6 Months

+370.56%

Year to Date

+402.79%

1 Year

+206.67%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
146 / 689
Overall Ranking
257 / 4737
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
4.000
Target Price
+112.77%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.62% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.52M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 62.65.
Undervalued
The company’s latest PE is -2.29, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 8.16M shares, increasing 14.61% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 40.48K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.32.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Ticker SymbolIPA
CompanyImmunoprecise Antibodies Ltd
CEODr. Jennifer Lynne Bath, Ph.D.
Websitehttps://www.ipatherapeutics.com/
KeyAI